To analyze the short- and long-term results of cavoportal anastomosis (CPA) and renoportal anastomosis (RPA) in 20 consecutive liver transplantation (LT) candidates with diffuse portal vein thrombosis (PVT).
Caval inflow to the graft (CIG) by CPA or RPA has been the most commonly used salvage technique to overcome the absolute contraindication for LT in case of diffuse PVT.
From 1996 to 2009, 3 patients (15%) underwent CPA and 17 patients (85%) had an RPA during LT. In addition to routine follow-up, patients were specifically evaluated for signs of portal hypertension (PHT) and for patency of the anastomoses. The follow-up ranged from 3 months to 12 years (median of 4.5 years).
Caval inflow to the graft was feasible in all attempted cases. In the short term (<6 months), 35% of patients had residual PHT-related complications (massive ascites and variceal bleeding). These resolved spontaneously or with endoscopic management. Three deaths occurred; none was related to PHT or shunt thrombosis. In the long term (>6 months), 1 death occurred because of recurrent variceal bleeding after RPA thrombosis. At last follow-up, all living patients [n = 13 (65%)] had normal liver function, no signs of PHT and patent anastomoses. There were no retransplantations. Graft and patient survival at 1, 3, and 5 years were 83%, 75%, and 60%, respectively.
Caval inflow to the graft is an efficacious salvage technique with satisfactory long-term results, considering the spontaneous outcome in patients denied LT because of diffuse PVT. Adequate preoperative management of PHT and its associated complications is vital in obtaining good results. In the long term, residual PHT resolves and the liver function returns to normal.
The short- and long-term results of caval inflow to the graft using cavoportal or renoportal anastomoses during liver transplantation in 20 patients with diffuse portal vein thrombosis were studied. This salvage technique yields satisfactory long-term results, considering the spontaneous outcome in patients denied liver transplantation because of diffused portal vein thromobosis.
*AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire, Villejuif Cedex, France
†Inserm, Unité 785, Villejuif Cedex, France
‡Inserm, Unité 1004, Villejuif Cedex, France.
Reprints: Daniel Azoulay, MD, PhD, AP-HP Hôpital Paul Brousse, Centre Hépato-Biliaire and Inserm, Unité 1004, 12 Ave Paul Vaillant-Couturier, 94800 Villejuif Cedex, France. E-mail: firstname.lastname@example.org.
Disclosure: The authors of this article state that they do not have anything to disclose as regards financial support or commercial sponsorship for the research described in this manuscript.